Pliant Therapeutics, Inc. (PLRX)
Develops cancer drugs targeting integrins to stop tumor growth
$1.07-0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-32.3%
The outlook
PLRX is trading near its 52-week lows, well below both short and long-term moving averages. Analyst sentiment is mixed, with an average price target suggesting significant upside from current levels, though coverage appears sparse. The overall technical picture leans bearish.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range2% of the way from its 52-week low to high
Price targetAvg target +134% vs current price
Analyst price target
~12-month · 2 analysts$2.50average target+133.6% vs now
Now $1.07
Low $2.00High $3.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$66.3M
52-wk high
$1.95
52-wk low
$1.05
50-day avg
$1.15
200-day avg
$1.31
Trailing P/E
—